Last reviewed · How we verify
SHR-1222
At a glance
| Generic name | SHR-1222 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Multiple Dose Study to Evaluate the Effect of SHR-1222 Injection in Postmenopausal Osteoporosis Patients (PHASE1)
- Effects of SHR-1222 on Vascular Inflammatory Factors in Patients With Low Bone Mass (NA)
- The PK/PD Study of A Single Subcutaneous Injection of SHR-1222 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-1222 CI brief — competitive landscape report
- SHR-1222 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI